Disease in a Dish: Creating Human Tissues In Vitro

Formulation Models

Predictive Formulation: Can Modeling Reduce Empirical Development?

David Alvaro, Ph.D.

Pharma's Almanac

Viral Vectors

Gene Therapy Manufacturing After the Capacity Boom

David Alvaro, Ph.D.

Pharma's Almanac

New Technology

What are the key bottlenecks preventing rapid adoption of novel technologies?

Pharma's Almanac

Heme-Onc

Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Heme-Onc

The Next Generation of Targeted Therapies in Hematologic Malignancies

DDC Development

Building Better Combination Products by Engaging Device Development Earlier

Loganathan S.

OneSource Specialty Pharma

Allogeneic CAR-T

Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Pediatric Oncology

Why Pediatric Oncology Needs Its Own Drug Development Paradigm

David Alvaro, Ph.D.

Pharma's Almanac

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

MPS

What Will It Take for Organ-on-Chip Data to Replace Animal Studies?

David Alvaro, Ph.D.

Pharma's Almanac